Miragen Therapeutics (United States)

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

Eva van Rooij, Lillian B. Sutherland, Jeffrey E. Thatcher et al. · Proceedings of the National Academy of Sciences · 2008 · 1.8K citations · Full text

Heart Failure, Immunology, Pathology +16

A Family of microRNAs Encoded by Myosin Genes Governs Myosin Expression and Muscle Performance

Eva van Rooij, Daniel Quiat, Brett A. Johnson et al. · Developmental Cell · 2009 · 945 citations · Full text

Muscle Function, Molecular Physiology, Skeletal Muscle +10

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Michael Boyle, Scott C. Bell, Michael W. Konstan et al. · The Lancet Respiratory Medicine · 2014 · 436 citations

Pathology, Cftr Corrector, Pulmonary Fibrosis +3

MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death

Arin B. Aurora, Ahmed I. Mahmoud, Xiang Luo et al. · Journal of Clinical Investigation · 2012 · 418 citations · Full text

Cardiac Muscle, Heart Failure, Immunology +21

A Cardiac MicroRNA Governs Systemic Energy Homeostasis by Regulation of MED13

Chad E. Grueter, Eva van Rooij, Brett A. Johnson et al. · Cell · 2012 · 358 citations · Full text